Trial Parameters
Brief Summary
The goal of this observational study is to describe the clinical features and long-term prognosis in patients diagnosed with autoimmune hepatitis (AIH) in China and assess the effectiveness and safety of AIH treatment options in a real-world setting.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 14 years * Probable or definite diagnosis of autoimmune hepatitis according to the International Autoimmune Hepatitis Study Group criteria * Availability of all following essential parameters at the initial diagnosis of AIH: including alanine transaminase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, immunoglobulin G, and platelet count * Provide informed consent Exclusion Criteria: * Have a concomitant diagnosis of primary biliary sclerosis, primary sclerosing cholangitis, immunoglobulin G 4-related cholangitis * Have an active infection with hepatitis B virus, hepatitis C virus, hepatitis delta virus, HIV, cytomegalovirus, or Epstein-Barr virus * Have a concomitant diagnosis of hepatocellular carcinoma or other malignant diseases before the diagnosis of AIH * Considered ineligible to the enrollment in the clinical study by the researcher